A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
about
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveSevere reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report.A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.A phase II, open-label trial of bortezomib (VELCADE(®)) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer.Prediction of outcome of non-small cell lung cancer patients treated with chemotherapy and bortezomib by time-course MALDI-TOF-MS serum peptide profiling.Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma.The role of proteasome inhibition in nonsmall cell lung cancerMass spectrometry-based serum and plasma peptidome profiling for prediction of treatment outcome in patients with solid malignancies.Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidancePlatinum plus bortezomib for the treatment of pediatric renal medullary carcinoma: Two cases.Targeting nuclear factor-kappa B to overcome resistance to chemotherapy.Positioning of proteasome inhibitors in therapy of solid malignancies.
P2860
Q26752368-8F870225-9081-4B7E-AC15-D4B7994BC63EQ30814901-9F6CFDAC-E81A-42E4-A833-661470404E28Q33409608-40F87425-59C2-4F63-BF2B-E482568E09C7Q33430874-27206941-6E29-4129-BCD3-EB69BD7C90D9Q33499899-B2CB7779-E82E-48AD-A18E-539F8DE336B1Q33753890-5753E3B2-B83B-4D75-A838-7451BC8F32B0Q35001441-C26D2234-01EC-4179-9E0A-3D1F98411EFCQ35238008-275022F9-4445-40BE-963E-D44971C368B7Q35836881-EF131343-D1ED-4698-BAA5-21D51129AA84Q37321943-134B3E01-9A66-44FB-86D5-55589F41DC48Q38019864-BFB399B9-AB45-4BEA-B2E6-529128141022Q38673319-9CD3005E-532D-4A48-AC7E-CC275D9EA30FQ38739048-C35EF9A7-AFF9-48FA-8BB3-45F33C82CA65Q40396447-DB9B1868-4DD1-446A-90AC-A5856AB7A1FAQ40751673-EC255E02-434E-4CC6-9727-04F8292DE085Q47353792-C30E930D-1F18-4ACC-A972-71EBDD92221A
P2860
A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@ast
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@en
type
label
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@ast
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@en
prefLabel
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@ast
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@en
P2093
P1476
A parallel dose-escalation stu ...... ts with advanced solid tumors.
@en
P2093
Bart C Kuenen
Egbert F Smit
Godefridus J Peters
Helgi van de Velde
Jens Voortman
Richard Honeywell
P304
P356
10.1158/1078-0432.CCR-07-0061
P407
P577
2007-06-01T00:00:00Z